The HER2 status has therapeutic implications, being a strong predictive marker for clinical benefit from HER2-targeted therapies such as trastuzumab and lapatinib, in both the metastatic and adjuvant breast cancer settings [52,53,54,55,56]. The gene discussed is ERBB2; the disease is breast carcinoma.